NEW YORK, July 14, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Aeri Pharmaceuticals, Inc. (NASDAQ: AERI), DaVita HealthCare Partners Inc. (NYSE: DVA), Prana Biotechnology Ltd. (NASDAQ: PRAN), Raptor Pharmaceutical Corp. (NASDAQ: RPTP) and Avanir Pharmaceuticals (NASDAQ: AVNR). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4726-100free.
--
Aeri Pharmaceuticals, Inc. Analyst Notes
On July 7, 2014, Aerie Pharmaceuticals, Inc. (Aerie Pharmaceuticals) announced that Michael McCleerey has been named to the newly created position of Company Vice President, Marketing, effective immediately. According to the Company, McCleerey will report directly to Thomas A. Mitro, Company President and Chief Operating Officer. The Company stated that McCleerey will be responsible for preparing for the commercial presence of the Company's lead product candidates. Commenting on the appointment, Company Chairman and CEO, Vicente Anido, Jr., Ph.D., said, "Aerie's continued progress in its lead development programs, including the recent reporting of positive results from our Phase 2b study of Roclatan', brings us closer to becoming a commercial-stage company. In light of this, we are pleased to announce the addition of Mike McCleerey to manage our marketing programs." The full analyst notes on Aeri Pharmaceuticals are available to download free of charge at:
http://www.analystsreview.com/Jul-14-2014/AERI/report.pdf
--
DaVita HealthCare Partners Inc. Analyst Notes
On July 9, 2014, DaVita HealthCare Partners Inc. (DaVita) reported that its division DaVita Kidney Care has named Martin Schreiber, M.D. as its new Vice President of Clinical Affairs for Home Modalities. DaVita Kidney Care CEO Javier Rodriguez, said, "DaVita's mission is to be the provider and partner of choice. To achieve this mission, we recruit top clinical leaders, like Dr. Schreiber. His commitment to continuous improvement in kidney care and role as an advocate for home dialysis are a great fit for the DaVita Village." The full analyst notes on DaVita are available to download free of charge at:
http://www.analystsreview.com/Jul-14-2014/DVA/report.pdf
--
Prana Biotechnology Ltd. Analyst Notes
On July 9, 2014, Prana Biotechnology Ltd.'s (Prana Biotechnology) stock went up by 9.21% to close at $2.61. Over the past five-day trading period, Company's stock increased by 19.17%, compared to the Nasdaq Composite, which lost 0.89% during the same trading period. The full analyst notes on Prana Biotechnologyare available to download free of charge at:
http://www.analystsreview.com/Jul-14-2014/PRAN/report.pdf
--
Raptor Pharmaceuticals Corp. Analyst Notes
On July 7, 2014, Raptor Pharmaceuticals Corp. (Raptor) announced that Company Executive Vice President, Strategy and Chief Operating Officer, Julie Anne Smith, as has been named as the Company's President and CEO-designate effective immediately, succeeding Christopher Starr, Ph.D., as CEO. According to the Company, Smith will join the Board effective January 1, 2015, and will oversee all operations based out of Raptor's headquarters in Novato, California. Additionally, the Company stated that Dr. Starr will remain on the Board of Directors and will consult on Raptor development projects following the succession. Llew Keltner, M.D., Ph.D., Chairman of the Board of Directors, said, "Julie is a proven leader and has been instrumental in the launch and commercialization of Raptor's first product, PROCYSBI. The Board of Raptor wholeheartedly supports her nomination and has confidence in her ability to lead Raptor to achieve its full potential." The full analyst notes on Raptor are available to download free of charge at:
http://www.analystsreview.com/Jul-14-2014/RPTP/report.pdf
--
Avanir Pharmaceuticals Analyst Notes
On July 9, 2014, Avanir Pharmaceuticals' stock reflected an increase of 3.74%, closing the day at $5.55. For the past three month trading period, Company's stock significantly increased by 43.40%, compared to the Nasdaq Composite, which gained 5.62% during the same trading period. The full analyst notes on Avanir Pharmaceuticals are available to download free of charge at:
http://www.analystsreview.com/Jul-14-2014/AVNR/report.pdf
--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
AnalystsReview.com
SOURCE Analysts Review
